Brief introduction of Hefei Tianmai Biotechnology Development Co., Ltd.

Hefei Tianmai Biotechnology Development Co., Ltd. was established in June 2007. Committed to introducing and absorbing international advanced biotechnology, specializing in the development and production of biopharmaceutical products. Hefei Tianmai currently has a registered capital of 752,944,600 yuan, covering an area of 167 mu. Hefei Tianmai Biological Company, located in Hefei Economic Development Zone Life Science and Technology Park, cooperated with Israeli technical team to introduce insulin seeds and production technology, successfully developed recombinant human insulin raw materials and preparation products, and established its own insulin research and development center, raw material production base and preparation production base. Tianmai Bio's factory and its production facilities are designed and built according to EU GMP and China GMP standards. At present, the R&D building has been built, covering an area of about 9,000 square meters. The first phase of insulin preparation workshop has been completed; Phase I insulin raw material workshop has been built (building area 17400 m2). The main production equipment comes from European and American countries. After the production facilities are completed, they will apply for double certification of EU GMP and China GMP. The development goal of Tianmai is to become an important R&D and production base of high-tech biomedical products at home and abroad, represented by recombinant human insulin and insulin analogues, and to build a first-class biopharmaceutical listed company in Asia within five years.